Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
PainChek Ltd ( (AU:PCK) ) has shared an announcement.
PainChek Ltd reported significant quarterly sales growth, with a 9% increase in net contracted licenses and a 10% rise in contracted annual recurring revenue, reaching A$5.4 million. The company’s expansion across the UK, Australia, and Canada, along with positive outcomes from a Scottish Inspectorate validation study, underscores its strong market presence and potential for further integration into national healthcare frameworks. These developments highlight PainChek’s strategic positioning within the aged care sector and its effectiveness in improving patient outcomes.
More about PainChek Ltd
PainChek Ltd is a company specializing in the development of smart device-based pain assessment and monitoring applications. Their primary product, the PainChek app, is a regulatory-cleared medical device that facilitates best-practice pain management, particularly for individuals who cannot reliably self-report their pain. The app is available on smartphones and tablets and combines AI technology with the Numerical Rating Scale to provide accurate pain assessments. PainChek operates globally with regulatory clearance in several countries and is widely used in aged care facilities.
Average Trading Volume: 1,892,005
Technical Sentiment Signal: Buy
Current Market Cap: A$73.68M
For an in-depth examination of PCK stock, go to TipRanks’ Overview page.